Expertise in
21
conditions

Dr. Scott Huntington

Hematology
Yale New Haven Hospital
20 York St, 
New Haven, CT 
Offers Telehealth
17 Years of Experience
Expertise in
21
conditions
Yale New Haven Hospital
20 York St, 
New Haven, CT 

Overview

Scott Huntington is a Hematologist in New Haven, Connecticut. Dr. Huntington has been practicing medicine for over 17 years is highly rated in 21 conditions, according to our data. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 108 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year

2009

Specialties

Hematology

Licenses

Internal Medicine in PA

Hospital Affiliations

Yale-New Haven Hospital
Bridgeport Hospital
Lawrence & Memorial Hospital
Greenwich Hospital Association -

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Yale New Haven Hospital
20 York St, New Haven, CT 06510
Other Locations
Smilow Cancer Hospital
35 Park St, New Haven, CT 06519

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
A Phase I, Open-label, Dose-escalation Study to Assess the Safety, Tolerability and Efficacy of the Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-Cell Non-Hodgkin Lymphoma (NHL)
A Phase I, Open-label, Dose-escalation Study to Assess the Safety, Tolerability and Efficacy of the Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-Cell Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Active_not_recruiting
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drugs: TGR-1202, Pembrolizumab
Study Phase: Phase 1
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: January 08, 2025
Intervention Type: Drug
Study Drug: Everolimus
Study Phase: Phase 2
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Enrollment Status: Completed
Publish Date: November 27, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
A Phase 1 Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
Enrollment Status: Terminated
Publish Date: August 25, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

108 Total Publications

Perceived Value of Transfusion Access and Hospice Services Among Patients With Blood Cancers.
Perceived Value of Transfusion Access and Hospice Services Among Patients With Blood Cancers.
Journal: JAMA network open
Published: November 05, 2025
Similar Doctors
Expertise in
24
conditions
Dr. Amer Zeidan
Hematology
Expertise in
24
conditions
Dr. Amer Zeidan
Hematology

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (0.1 miles away)
203-200-4363
Languages Spoken:
English
See accepted insurances

Amer Zeidan is a Hematologist in New Haven, Connecticut. Dr. Zeidan is highly rated in 24 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
30
conditions
Dr. Nikolai Podoltsev
Hematology
Expertise in
30
conditions
Dr. Nikolai Podoltsev
Hematology

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (0.1 miles away)
203-200-4363
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nikolai Podoltsev is a Hematologist in New Haven, Connecticut. Dr. Podoltsev is highly rated in 30 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Myeloproliferative Neoplasms (MPN), Polycythemia Vera, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
14
conditions
Dr. Mario Sznol
Hematology | Oncology
Expertise in
14
conditions
Dr. Mario Sznol
Hematology | Oncology

Yale University

20 York St, 
New Haven, CT 
 (0.1 miles away)
203-688-2433
Experience:
44+ years
Languages Spoken:
English
See accepted insurances

Mario Sznol is a Hematologist and an Oncologist in New Haven, Connecticut. Dr. Sznol has been practicing medicine for over 44 years is highly rated in 14 conditions, according to our data. His top areas of expertise are Melanoma, Renal Cell Carcinoma (RCC), Melanoma of the Eye, and WT1-Related Wilms Tumor Syndromes.

Frequently Asked Questions about Dr. Scott Huntington

How do I make an appointment with Dr. Scott Huntington?

You can book an appointment with Dr. Scott Huntington by calling their office at 203-200-4363. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Scott Huntington a top-rated expert for Chronic B-Cell Leukemia (CBCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Scott Huntington is classified as an Elite expert for Chronic B-Cell Leukemia (CBCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Scott Huntington specialize in?

While Dr. Scott Huntington is a Hematology, they have specific expertise in Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), and Non-Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Scott Huntington participate in research or clinical trials?

Yes. Dr. Scott Huntington has published 108 articles and abstracts on conditions like Chronic B-Cell Leukemia (CBCL). You can view a list of Dr. Scott Huntington's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Scott Huntington accept my insurance?

Dr. Scott Huntington accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 203-200-4363 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Huntington's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 11 Advanced Conditions
View All 36 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile